Patents by Inventor Mohamad Morsey

Mohamad Morsey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CANINIZED ANTIBODIES
    Publication number: 20160311902
    Abstract: The present invention discloses caninized antibodies with specific properties. The present invention also discloses caninized murine antibodies againstcanine PD-1 that have a high binding affinity for canine PD-1. The invention further discloses the use of the caninized antibodies of the present invention in the treatment of cancer in dogs.
    Type: Application
    Filed: December 19, 2014
    Publication date: October 27, 2016
    Applicant: Intervet Inc.
    Inventors: Mohamad Morsey, Yuanzheng Zhang, Ian Tarpey
  • Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
    Patent number: 9409954
    Abstract: Recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: August 9, 2016
    Assignee: Intervet Inc.
    Inventors: Stephanie Cook, Mohamad Morsey, Gary Petersen, Paulus Jacobus Antonius Sondermeijer
  • RECOMBINANT NON-PATHOGENIC MAREK'S DISEASE VIRUS CONSTRUCTS ENCODING INFECTIOUS LARYNGOTRACHEITIS VIRUS AND NEWCASTLE DISEASE VIRUS ANTIGENS
    Publication number: 20150344528
    Abstract: The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.
    Type: Application
    Filed: November 5, 2014
    Publication date: December 3, 2015
    Inventors: Stephanie Cook, Mohamad Morsey, Gary Petersen, Paulus Jacobus Antonius Sondermeijer
  • Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
    Patent number: 8932604
    Abstract: Recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: January 13, 2015
    Assignee: Intervet Inc.
    Inventors: Stephanie Cook, Mohamad Morsey, Gary Petersen, Paulus Jacobus Antonius Sondermeijer
  • Canine thymic stromal lymphopoietin protein and uses thereof to treat allergic symptoms
    Patent number: 8791242
    Abstract: The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: July 29, 2014
    Assignee: Intervet Inc.
    Inventors: Jeanine D. Mattson, Daniel M. Gorman, Rene de Waal Malefyt, Mohamad A. Morsey
  • vaccines
    Patent number: 8784829
    Abstract: The present invention relates to polynucleotide sequences encoding novel Lawsonia intracellularis polypeptides. It also relates to DNA fragments, recombinant plasmid DNA and live recombinant microorganisms comprising these sequences. Moreover, the invention relates to polypeptides encoded by these nucleotide sequences. The invention also relates to immunogenic compositions for prevention of Lawsonia intracellularis infections and methods for the preparation of these immunogenic compositions. The invention also relates to diagnostic tests for the detection of Lawsonia intracellularis DNA, the detection of Lawsonia intracellularis antigens and detection of antibodies against Lawsonia intracellularis.
    Type: Grant
    Filed: October 21, 2009
    Date of Patent: July 22, 2014
    Assignee: Intervet Inc.
    Inventors: Mohamad A. Morsey, Stephanie M. Cook, Yuanzheng Zhang, Qing Zhang
  • bacterium of a novel serotype, vaccine based on that bacterium, antibodies suitable for diagnosing the novel serotype and hybridomas for producing the said antibodies
    Patent number: 8557254
    Abstract: This invention pertains to Lawsonia intracellularis bacterium of a serotype which is reactive with monoclonal antibody INT-LIC-02-02 as produced by hybridoma INT-LIC-02-02 deposited with the Collection Nationale de Cultures de Micro-organismes of the Institut Pasteur at Paris France under nr. CNCM I-4049 but which is not reactive with antibody INT-LIC-01-28 as produced by hybridoma INT-LIC-01-28 deposited with the Collection Nationale de Cultures de Micro-organismes of the Institut Pasteur at Paris France under nr. CNCM I-4048. The invention also pertains to vaccines for protection against an infection with Lawsonia intracellularis based on those novel bacteria, antibodies suitable for diagnosing the novel Lawsonia intracellularis serotype and hybridomas for producing the said antibodies.
    Type: Grant
    Filed: July 20, 2009
    Date of Patent: October 15, 2013
    Assignees: Intervet Inc., Intervet International B.V.
    Inventors: Yvonne Maria Johanna Corina Biermann, Mohamad Morsey, Antonius Arnoldus Christiaan Jacobs, Carla Christina Schrier
  • CANINE THYMIC STROMAL LYMPHOPOIETIN PROTEIN AND USES THEREOF
    Publication number: 20130183291
    Abstract: The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.
    Type: Application
    Filed: November 11, 2011
    Publication date: July 18, 2013
    Inventors: Jeanine D. Mattson, Daniel M. Gorman, Rene de Waal Malefyt, Mohamad A. Morsey
  • Anti-IGE Vaccines
    Publication number: 20120321651
    Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.
    Type: Application
    Filed: August 22, 2012
    Publication date: December 20, 2012
    Applicant: Pfizer Inc.
    Inventors: Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
  • Anti-IgE vaccines
    Patent number: 8273356
    Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.
    Type: Grant
    Filed: November 24, 2009
    Date of Patent: September 25, 2012
    Assignee: Pfizer Inc.
    Inventors: Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
  • Fusion proteins comprising canine thymic stromal lymphopoietin protein and uses thereof
    Patent number: 8076456
    Abstract: The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: December 13, 2011
    Assignee: Intervet Inc.
    Inventors: Jeanine D. Mattson, Daniel M. Gorman, Rene de Waal Malefyt, Mohamad A. Morsey
  • LAWSONIA INTRACELLULARIS VACCINES
    Publication number: 20110200631
    Abstract: The present invention relates to polynucleotide sequences encoding novel Lawsonia intracellularis polypeptides. It also relates to DNA fragments, recombinant plasmid DNA and live recombinant microorganisms comprising these sequences. Moreover, the invention relates to polypeptides encoded by these nucleotide sequences. The invention also relates to immunogenic compositions for prevention of Lawsonia intracellularis infections and methods for the preparation of these immunogenic compositions. The invention also relates to diagnostic tests for the detection of Lawsonia intracellularis DNA, the detection of Lawsonia intracellularis antigens and detection of antibodies against Lawsonia intracellularis.
    Type: Application
    Filed: October 21, 2009
    Publication date: August 18, 2011
    Inventors: Mohamad A. Morsey, Yuanzheng Zhang, Qing Zhang, Stephanie M. Cook
  • LAWSONIA INTRACELLULARIS BACTERIUM OF A NOVEL SEROTYPE, VACCINE BASED ON THAT BACTERIUM, ANTIBODIES SUITABLE FOR DIAGNOSING THE NOVEL LAWSONIA INTRACELLULARIS SEROTYPE AND HYBRIDOMAS FOR PRODUCING THE SAID ANTIBODIES
    Publication number: 20110129500
    Abstract: This invention pertains to Lawsonia intracellularis bacterium of a serotype which is reactive with monoclonal antibody INT-LIC-02-02 as produced by hybridoma INT-LIC-02-02 deposited with the Collection Nationale de Cultures de Micro-organismes of the Institut Pasteur at Paris France under nr. CNCM I-4049 but which is not reactive with antibody INT-LIC-01-28 as produced by hybridoma INT-LIC-01-28 deposited with the Collection Nationale de Cultures de Micro-organismes of the Institut Pasteur at Paris France under nr. CNCM I-4048. The invention also pertains to vaccines for protection against an infection with Lawsonia intracellularis based on those novel bacteria, antibodies suitable for diagnosing the novel Lawsonia intracellularis serotype and hybridomas for producing the said antibodies.
    Type: Application
    Filed: July 20, 2009
    Publication date: June 2, 2011
    Inventors: Yvonne Maria Johanna Corina Biermann, Mohamad Morsey, Antonius Arnoldus Christiaan Jacobs, Carla Christina Schrier
  • Anti-IgE vaccines
    Patent number: 7897151
    Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: March 1, 2011
    Assignee: Pharmacia & Upjohn Company, LLC
    Inventors: Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
  • CANINE THYMIC STROMAL LYMPHOPOIETIN PROTEIN AND USES THEREOF
    Publication number: 20110033478
    Abstract: The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.
    Type: Application
    Filed: March 10, 2010
    Publication date: February 10, 2011
    Inventors: JEANINE D. MATTSON, DANIEL M. GORMAN, RENE DE WAAL MALEFYT, MOHAMAD A. MORSEY
  • Canine thymic stromal lymphopoietin protein and uses thereof
    Patent number: 7718772
    Abstract: The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: May 18, 2010
    Assignee: Schering-Plough Animal Health Corporation
    Inventors: Jeanine D. Mattson, Daniel M. Gorman, Rene de Waal Malefyt, Mohamad A. Morsey
  • ANTI-IGE VACCINES
    Publication number: 20100113361
    Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.
    Type: Application
    Filed: November 24, 2009
    Publication date: May 6, 2010
    Applicant: PFIZER INC.
    Inventors: Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
  • Non-anaphylactogenic IgE fusion proteins
    Patent number: 7420047
    Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of IgE molecules from two unrelated species as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides.
    Type: Grant
    Filed: September 7, 2005
    Date of Patent: September 2, 2008
    Assignees: Pfizer Inc., Pfizer Products
    Inventors: Mohamad A. Morsey, Tracy M. Brown
  • Non-Anaphylactogenic IgE Fusion Proteins
    Publication number: 20080193439
    Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of IgE molecules from two unrelated species as vaccines for the treatment and prevention of IgE-mediated allergic disorders, in particular, the invention provides compositions for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides.
    Type: Application
    Filed: March 14, 2008
    Publication date: August 14, 2008
    Applicants: PFIZER, INC., PFIZER PRODUCTS, INC.
    Inventors: Mohamad A. Morsey, Tracy M. Brown
  • Canine Thymic Stromal Lymphopoietin Protein and Uses Thereof
    Publication number: 20080152620
    Abstract: The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.
    Type: Application
    Filed: December 11, 2007
    Publication date: June 26, 2008
    Inventors: Jeanine D. Mattson, Daniel M. Gorman, Rene de Waal Malefyt, Mohamad A. Morsey